Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 10/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.59 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.59 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2348323 | 1.00 | NR1I2 (0.70) | NR1I2CYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL2343463 | 0.94 | NR1I2 (0.71) | NR1I2CYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL14079867 | 0.93 | NR1I2 (0.81) | NR1I2CYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL12450298 | 0.93 | NR1I2 (0.81) | NR1I2CYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL2348962 | 0.91 | NR1I2 (0.73) | NR1I2CYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL14391683 | 0.90 | KCNH2 (0.69) | NR1I2CYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL12809626 | 0.86 | KCNH2 (0.80) | NR1I2CYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL14391684 | 0.85 | KCNH2 (0.71) | NR1I2CYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL13843582 | 0.85 | NR1I2 (0.70) | NR1I2CYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL4905819 | 0.85 | NR1I2 (0.70) | NR1I2CYP3A4CYP2C9CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521444-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-21 | — | — | US | disclosed |
| US-7521444-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-21 | — | — | US | disclosed |
| US-20080226590-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
| US-20080226590-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
| WO-2008112841-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080226590-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | NR1I2 189/4885CYP3A4 214/4885CYP2C9 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.